Lexington Biosciences Inc. (LXGTF)

[LittleBlondie]

LXGTF Engages Clinical Research Organization!!

“WITH TODAY’S (11/30/17) ANNOUNCEMENT (LXGTF)’S PLANS ARE NOW ADVANCING TO INITIATE COMMENCEMENT OF A PILOT CLINICAL RESEARCH STUDY DESIGNED TO BEGIN GATHERING THE FOUNDATIONAL DATASET AIMED AT SUPPORTING FDA CLEARANCE.”

VANCOUVER, BC–(Marketwired – Nov 30, 2017) – Lexington Biosciences, Inc. ( CSE : LNB ) ( OTCQB : LXGTF ) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the engagement of San Francisco Bay Area-based Diablo Clinical Research to conduct its upcoming HeartSentry pilot clinical studies.

Lexington recently announced delivery of its initial order of HeartSentry devices slated for clinical trials. With today’s announcement, plans are now advancing to initiate commencement of a pilot clinical research study designed to begin gathering the foundational dataset aimed at supporting FDA clearance.

Diablo Clinical Research has specialized in clinical research for over 22 years. Founded in 1995, Diablo’s team has conducted over 600 studies with thousands of patients and in the process, has assembled a database comprising over 15,000 patients who have either completed a study, are currently enrolled in a study, or have expressed interest in future clinical study participation. The firm has 4 MDs on staff with specialties in endocrinology, internal medicine, and cardiology. Find out more at: www.diabloclinical.com.

Dr. Geoff Tison, Cardiologist and Assistant Professor in the Division of Cardiology at the University of California San Francisco and Medical Advisor to the company comments, “After a fifteen-year research process, I am excited to see Lexington beginning their clinical research efforts in order to gather clinical study data for the HeartSentry device. With the recent publication of the more stringent American Heart Association hypertension management guidelines, there is increased awareness of the need to more closely monitor patients for cardiovascular risk factors, which HeartSentry is well positioned to do.”

Lexington’s President Eric Willis comments, “After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively. They have been extremely helpful in the determination process which has led to today’s announcement. We are excited to begin this next step of our development phase, and look forward to sharing quantifiable results in the near future.

http://techstockinsider.com/lexington-biosciences-lxgtf-lnb-engages-clinical-research-organization/?utm_medium=Social&utm_source=TSI_Social_Link&utm_campaign=TSI_Social_1130